Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
… ProQR Announces Third Quarter 2023 Operating and Financial … NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We expect that the body of data on our platform and …
… ProQR Announces Second Quarter 2023 Operating and Financial … of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Announces First Quarter 2022 Operating and Financial … & CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … for the same period last year. Research and development (R&D) costs were €13.4 million for the quarter ended March 31, …
… ProQR Announces Second Quarter 2024 Operating and Financial … & CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company … in Q2 was received in July. Research and development (R&D) costs were €7.1 million for the quarter ended June 30, …
… ProQR Announces Proposed Underwritten Public Offering of … & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a …
… ProQR Announces Proposed Underwritten Public Offering of … and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a …
… ProQR Announces Results for the First Quarter of 2017 Key … Investigational new drug (IND) application for QR-110, ProQR’s lead program in ophthalmology, was cleared by the FDA … Usher syndrome. The Company announced that it will host an R&D Day on June 15 th in New York where Company executives …
… ProQR Announces Proposed Underwritten Public Offering of … and CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters …